Brose MS - Search Results

1

Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers.

Huang J, Domchek SM, Brose MS, Rebbeck TR, Nathanson KL, Weber BL. Huang J, et al. Among authors: brose ms. J Med Genet. 2004 Nov;41(11):e120. doi: 10.1136/jmg.2004.022913. J Med Genet. 2004. PMID: 15520402 Free PMC article. No abstract available.

2

Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Brose MS, et al. J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72. doi: 10.1093/jnci/94.18.1365. J Natl Cancer Inst. 2002. PMID: 12237282

3

BRAF and RAS mutations in human lung cancer and melanoma.

Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. Brose MS, et al. Cancer Res. 2002 Dec 1;62(23):6997-7000. Cancer Res. 2002. PMID: 12460918

4

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Satyamoorthy K, et al. Among authors: brose ms. Cancer Res. 2003 Feb 15;63(4):756-9. Cancer Res. 2003. PMID: 12591721

5

Absence of BRAF mutations in UV-protected mucosal melanomas.

Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL. Edwards RH, et al. Among authors: brose ms. J Med Genet. 2004 Apr;41(4):270-2. doi: 10.1136/jmg.2003.016667. J Med Genet. 2004. PMID: 15060100 Free PMC article.

6

Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.

Brose MS, Volpe P, Paul K, Stopfer JE, Colligon TA, Calzone KA, Weber BL. Brose MS, et al. Genet Test. 2004 Summer;8(2):133-8. doi: 10.1089/gte.2004.8.133. Genet Test. 2004. PMID: 15345110

7

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH. Spittle C, et al. Among authors: brose ms. J Mol Diagn. 2007 Sep;9(4):464-71. doi: 10.2353/jmoldx.2007.060191. Epub 2007 Aug 9. J Mol Diagn. 2007. PMID: 17690212 Free PMC article.

8

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. Flaherty KT, et al. Among authors: brose ms. Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. Clin Cancer Res. 2008. PMID: 18676756 Clinical Trial.

9

Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues.

Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS. Ma C, et al. Among authors: brose ms. Cancer Biol Ther. 2009 May;8(10):907-16. doi: 10.4161/cbt.8.10.8132. Epub 2009 May 9. Cancer Biol Ther. 2009. PMID: 19276661

10

Her-2 targeted therapy: beyond breast cancer and trastuzumab.

Flaherty KT, Brose MS. Flaherty KT, et al. Among authors: brose ms. Curr Oncol Rep. 2006 Mar;8(2):90-5. doi: 10.1007/s11912-006-0042-4. Curr Oncol Rep. 2006. PMID: 16507217 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters